Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions. (Q34488656)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21041705%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions (English)

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21041705%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

0 references

Kelsey Loeliger

6

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21041705%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Phillip Scheinberg

10

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21041705%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

author name string

Elaine M Sloand

1

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21041705%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Matthew J Olnes

2

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21041705%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Aarthie Shenoy

3

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21041705%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Barbara Weinstein

4

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21041705%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Carol Boss

5

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21041705%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Colin O Wu

7

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21041705%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Kenneth More

8

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21041705%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

A John Barrett

9

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21041705%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Neal S Young

11

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21041705%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

language of work or name

0 references

publication date

1 November 2010

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21041705%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Journal of Clinical Oncology

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21041705%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

28

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21041705%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

35

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21041705%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

5166-5173

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21041705%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Sex hormones, acting on the TERT gene, increase telomerase activity in human primary hematopoietic cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020689

6 July 2018

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020689

6 July 2018

Pharmacokinetics of alemtuzumab in combination with fludarabine in patients with relapsed or refractory B-cell chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020689

6 July 2018

Haploinsufficiency of RPS14 in 5q- syndrome is associated with deregulation of ribosomal- and translation-related genes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020689

6 July 2018

Morbidity and mortality in rheumatoid arthritis patients with prolonged therapy-induced lymphopenia: twelve-year outcomes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020689

6 July 2018

Telomere maintenance and human bone marrow failure

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020689

6 July 2018

Ribosomal protein S27-like, a p53-inducible modulator of cell fate in response to genotoxic stress

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020689

6 July 2018

Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020689

6 July 2018

Alemtuzumab in chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020689

6 July 2018

Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020689

6 July 2018

Granulocyte colony-stimulating factor preferentially stimulates proliferation of monosomy 7 cells bearing the isoform IV receptor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020689

6 July 2018

CAMPATH: from concept to clinic

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020689

6 July 2018

Present experience with Campath-1H in organ transplantation and its potential use in pediatric recipients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020689

6 July 2018

A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020689

6 July 2018

Immunosuppressive treatments for myelodysplastic syndromes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020689

6 July 2018

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020689

6 July 2018

New approaches to the treatment of myelodysplasia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020689

6 July 2018

The effect of treatment with Campath-1H in patients with autoimmune cytopenias

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020689

6 July 2018

World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020689

6 July 2018

CAMPATH-1H in rheumatoid arthritis--an intravenous dose-ranging study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020689

6 July 2018

Treatment of active refractory rheumatoid arthritis with humanized monoclonal antibody CAMPATH-1H administered by daily subcutaneous injection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020689

6 July 2018

Optimal two-stage designs for phase II clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020689

6 July 2018

Infection in the myelodysplastic syndromes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020689

6 July 2018

A pilot dose-escalating study of alemtuzumab plus cyclosporine for patients with bone marrow failure syndrome.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020689

27 October 2018

Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020689

27 October 2018

Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020689

27 October 2018

Maintenance therapy with a monthly injection of alemtuzumab prolongs response duration in patients with refractory B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (B-CLL/SLL).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020689

27 October 2018

Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020689

27 October 2018

Antithymocyte globulin and cyclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndromes

1 reference

https://pubmed.ncbi.nlm.nih.gov/21041705

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow

1 reference

https://pubmed.ncbi.nlm.nih.gov/21041705

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia

1 reference

https://pubmed.ncbi.nlm.nih.gov/21041705

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome

1 reference

https://pubmed.ncbi.nlm.nih.gov/21041705

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Myelodysplastic syndromes: incidence and survival in the United States

1 reference

https://pubmed.ncbi.nlm.nih.gov/21041705

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Induction of Fas (Apo-1, CD95)-mediated apoptosis of activated lymphocytes by polyclonal antithymocyte globulins

1 reference

https://pubmed.ncbi.nlm.nih.gov/21041705

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The nephrotoxicity of new and old immunosuppressive drugs

1 reference

https://pubmed.ncbi.nlm.nih.gov/21041705

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Abnormal cytogenetic clones in patients with aplastic anaemia: response to immunosuppressive therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/21041705

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A pilot study of antithymocyte globulin (ATG) in the treatment of patients with 'low-risk' myelodysplasia

1 reference

https://pubmed.ncbi.nlm.nih.gov/21041705

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes

1 reference

https://pubmed.ncbi.nlm.nih.gov/21041705

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prevalence and causes of anaemia in a geriatric hospitalized population

1 reference

https://pubmed.ncbi.nlm.nih.gov/21041705

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulin

1 reference

https://pubmed.ncbi.nlm.nih.gov/21041705

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2010.29.7010

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21041705%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21041705%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21041705%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34488656&oldid=1627847824"